# Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

> **NCT04140162** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04140162
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-05
- **Primary completion:** 2024-05-02
- **Final completion:** 2026-05-02
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140162, "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04140162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*